Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II) : an international, double-blind, randomised placebo-controlled trial

Cuzick, JackSestak, IvanaForbes, John F.Dowsett, MitchKnox, JillCawthorn, SimonSaunders, ChristobelRoche, NicolaMansel, Robert E.von Minckwitz, GunterBonanni, BernardoPalva, TiinaHowell, AnthonyIBIS-II investigators2018-12-042018-12-042014-03-22Cuzick, J, Sestak, I, Forbes, J F, Dowsett, M, Knox, J, Cawthorn, S, Saunders, C, Roche, N, Mansel, R E, von Minckwitz, G, Bonanni, B, Palva, T, Howell, A & IBIS-II investigators 2014, 'Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II) : an international, double-blind, randomised placebo-controlled trial', The Lancet, vol. 383, no. 9922, pp. 1041-1048. https://doi.org/10.1016/S0140-6736(13)62292-80140-6736http://hdl.handle.net/2164/11551This study was funded by Cancer Research UK (C569/A5032), the National Health and Medical Research Council Australia (GNT300755, GNT569213), Sanofi-Aventis, and AstraZeneca. Sanofi-Aventis and AstraZeneca provided anastrozole and matching placebo. The study sponsor was Queen Mary University of London.8462614engSDG 3 - Good Health and Well-beingR MedicineCancer Research UKC569/A5032RAnastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II) : an international, double-blind, randomised placebo-controlled trialJournal article10.1016/S0140-6736(13)62292-83839922